▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #555 by analyst upside · 2026-09-29
EVMN
Evommune, Inc.
Healthcare · Market Cap $304M · P/E 0x
ANALYST PRICE TARGET
+187.5%
implied upside to consensus target
Current Price $8.39
Consensus Target $24.12
Bull Target $30.0
Bear Target $18.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
2
Sell
0
52-Week Low $8.12
52-Week High $33.2
YTD Return -51.5%
FUNDAMENTALS
Market Cap $304M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-11.87
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $10M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.12
52-Week High $33.2
Current Price $8.39
Bear Target $18.0
Bull Target $30.0
● Now $8.39 ● Target $24.12
TRADING DATA
Avg Volume 855K
YTD Return -51.5%
Analyst Count 8
Consensus Buy
Upside to Target +187.5%
Last Updated 2026-09-29

ANALYST SUMMARY

Evommune, Inc. (EVMN) is currently trading at $8.39 with a Wall Street consensus price target of $24.12, implying potential upside of 187.5% over the next 12 months. 8 analysts currently cover EVMN, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $30.0, while the most cautious has a target of $18.0.

EVMN operates in the Healthcare sector with a market capitalisation of $304M. The stock is down 51.5% year-to-date and is currently trading near the lower end of its 52-week range of $8.12 – $33.2.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AGEN +179.3%
Agenus Inc.
$426M · P/E 3.2x · Buy
SABS +261.9%
SAB Biotherapeutics, Inc.
$293M · P/E 14.0x · Buy
XFOR +284.7%
X4 Pharmaceuticals, Inc.
$299M · P/E 2.1x · Buy
CGEN +97.4%
Compugen Ltd.
$221M · P/E 6.3x · Buy
ASMB +120.2%
Assembly Biosciences, Inc.
$481M · P/E 19.0x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for EVMN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners - Reiterated
Outperform → Outperform 2026-09-09 29% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-09-09 Building track record
HC Wainwright & Co. reit
Neutral → Neutral 2026-09-09 31% win rate (48 calls)
Needham ● Initiated
Buy 2026-08-26 20% win rate (5 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-08-07 Building track record
HC Wainwright & Co. reit
Neutral → Neutral 2026-08-03 31% win rate (48 calls)
Morgan Stanley - Reiterated
Overweight → Overweight 2026-06-30 Building track record
HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-06-30 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
32
out of 100
Coverage depth
17/30
Consensus clarity
1/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →